The Primary Progressive Multiple Sclerosis (PPMS) drugs in development market research report provides comprehensive information on the therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Primary Progressive Multiple Sclerosis (PPMS). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Primary Progressive Multiple Sclerosis (PPMS) and features dormant and discontinued products.
GlobalData tracks 30 drugs in development for Primary Progressive Multiple Sclerosis (PPMS) by 28 companies/universities/institutes. The top development phase for Primary Progressive Multiple Sclerosis (PPMS) is phase ii with 12 drugs in that stage. The Primary Progressive Multiple Sclerosis (PPMS) pipeline has 28 drugs in development by companies and two by universities/ institutes. Some of the companies in the Primary Progressive Multiple Sclerosis (PPMS) pipeline products market are: Sanofi, Genentech USA and Millennium Pharmaceuticals.
The key targets in the Primary Progressive Multiple Sclerosis (PPMS) pipeline products market include Tyrosine Protein Kinase BTK, B Lymphocyte Antigen CD20, and B Lymphocyte Antigen CD19.
The key mechanisms of action in the Primary Progressive Multiple Sclerosis (PPMS) pipeline product include B Lymphocyte Antigen CD20 Inhibitor with two drugs in Pre-Registration. The Primary Progressive Multiple Sclerosis (PPMS) pipeline products include seven routes of administration with the top ROA being Oral and seven key molecule types in the Primary Progressive Multiple Sclerosis (PPMS) pipeline products market including Small Molecule, and Cell Therapy.
Primary Progressive Multiple Sclerosis (PPMS) overview
Primary progressive multiple sclerosis (PPMS) is a rare and disabling form of MS that affects the brain, spinal cord, and optic nerves. Unlike other types of MS, PPMS does not have relapses or remissions, but causes steady worsening of neurological functions from the onset. PPMS affects about 10% of people with MS, and it occurs equally in men and women. The average age of diagnosis is around 40 years. The symptoms of PPMS vary from person to person, but they often include problems with walking, balance, vision, muscle weakness, pain, fatigue, cognitive impairment, and bladder and bowel dysfunction. There is no cure for PPMS, but treatments can help manage symptoms and improve quality of life. PPMS is diagnosed based on clinical history, physical examination, MRI scans, spinal fluid analysis, and other tests.
For a complete picture of Primary Progressive Multiple Sclerosis (PPMS)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
